{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:12:45Z","timestamp":1773760365325,"version":"3.50.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Folylpolyglutamate synthetase (FPGS) is a crucial enzyme in both cellular folate homeostasis and the intracellular retention of folate analogue drugs such as methotrexate (MTX), which is commonly used for the treatment of (pediatric) leukemia and the anchor drug in rheumatoid arthritis (RA) treatment. To date, assessment of FPGS catalytic activity relies on assays using radioactive substrates that are labor-intensive and require relatively large numbers of cells. Here, we describe a nonradioactive, ultra\u2013high-performance liquid chromatography\u2013tandem mass spectrometer (UHPLC-MS\/MS)\u2013based method allowing for sensitive and accurate measurements of FPGS activity in low cell numbers (ie, 1\u20132 \u00d7 10<jats:sup>6<\/jats:sup>) of biological specimens, including leukemic blast cells of acute lymphoblastic leukemia patients and peripheral blood mononuclear cells of patients with RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The UHPLC-MS\/MS assay was validated with 2 CCRF-CEM human leukemia cells, one proficient and one deficient in FPGS activity. Linearity of time and protein input were tested by measuring FPGS activity at 30\u2013180 minutes of incubation time and 10\u2013300 mcg protein extract. In addition, FPGS enzyme kinetic parameters were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The FPGS enzymatic assay showed a linear relation between FPGS activity and protein input (R<jats:sup>2<\/jats:sup> \u2265 0.989) as well as incubation time (R<jats:sup>2<\/jats:sup> \u2265 0.996). Moreover, the UHPLC-MS\/MS method also allowed for evaluation of FPGS enzyme kinetic parameters revealing K<jats:sub>m<\/jats:sub> values for the substrates MTX and L-glutamic acid of 64 \u00b5mol\/L and 2.2 mmol\/L, respectively. The mean FPGS activity of acute lymphoblastic leukemia blast cells (n = 4) was 3-fold higher than that of CCRF-CEM cells and 44-fold and 88-fold higher than that of peripheral blood mononuclear cells from MTX-naive (n = 9) and MTX-treated RA patients (n = 6), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Collectively, given its sensitivity with low cell numbers and avoidance of radioactive substrates, UHPLC-MS\/MS\u2013based analysis of FPGS activity may be eligible for routine therapeutic drug monitoring of MTX in RA and leukemia for therapy (non)response evaluations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000638","type":"journal-article","created":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T01:45:49Z","timestamp":1555724749000},"page":"598-606","source":"Crossref","is-referenced-by-count":11,"title":["Development and Validation of a Sensitive UHPLC-MS\/MS\u2013Based Method for the Analysis of Folylpolyglutamate Synthetase Enzymatic Activity in Peripheral Blood Mononuclear Cells: Application in Rheumatoid Arthritis and Leukemia Patients"],"prefix":"10.1097","volume":"41","author":[{"given":"Ittai B.","family":"Muller","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, Amsterdam University Medical Centers, Location VUmc;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marry","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Amsterdam University Medical Centers, Location VUmc;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard A.","family":"Struys","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Amsterdam University Medical Centers, Location VUmc;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paniz","family":"Heydari","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Amsterdam University Medical Centers, Location VUmc;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renske C. F.","family":"Hebing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Location Reade;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike T.","family":"Nurmohamed","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Location Reade;"},{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Location VUmc; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conny","family":"van der Laken","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Location VUmc; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem F.","family":"Lems","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Location Reade;"},{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Location VUmc; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Cloos","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam University Medical Centers, Location VUmc, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Location VUmc; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"de Jonge","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Amsterdam University Medical Centers, Location VUmc;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann Rheum Dis."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.1993.11.1.5","article-title":"Karnofsky memorial lecture. Ode to methotrexate","volume":"11","author":"Bertino","year":"1993","journal-title":"J Clin Oncol."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/art.38094","article-title":"Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis","volume":"65","author":"Blits","year":"2013","journal-title":"Arthritis Rheum."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","article-title":"Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis","volume":"47","author":"Wessels","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1016\/S0021-9258(19)70697-8","article-title":"Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products","volume":"255","author":"McGuire","year":"1980","journal-title":"J Biol Chem."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.drup.2016.06.004","article-title":"Folylpoly-gamma-glutamate synthetase: a key determinant of folate homeostasis and antifolate resistance in cancer","volume":"28","author":"Raz","year":"2016","journal-title":"Drug Resist Updat."},{"key":"R10-20230814","first-page":"2532","article-title":"Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2","volume":"59","author":"Hooijberg","year":"1999","journal-title":"Cancer Res."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1073\/pnas.96.12.6914","article-title":"MRP3, an organic anion transporter able to transport anti-cancer drugs","volume":"96","author":"Kool","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.drup.2006.09.001","article-title":"The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis","volume":"9","author":"Assaraf","year":"2006","journal-title":"Drug Resist Updat."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist Updat."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/art.1780391203","article-title":"Molecular therapeutics. Methotrexate and its mechanism of action","volume":"39","author":"Cronstein","year":"1996","journal-title":"Arthritis Rheum."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nat Rev Rheumatol."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ijc.10829","article-title":"Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines","volume":"103","author":"Liani","year":"2003","journal-title":"Int J Cancer"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0006-2952(01)00824-3","article-title":"Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis","volume":"63","author":"Mauritz","year":"2002","journal-title":"Biochem Pharmacol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.3324\/haematol.2016.142794","article-title":"The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia","volume":"101","author":"Wojtuszkiewicz","year":"2016","journal-title":"Haematologica."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.V93.5.1677","article-title":"Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia","volume":"93","author":"Rots","year":"1999","journal-title":"Blood"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1046\/j.1365-2141.2000.02070.x","article-title":"Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia","volume":"110","author":"Rots","year":"2000","journal-title":"Br J Haematol."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ijc.2910510613","article-title":"In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate","volume":"51","author":"van der Laan","year":"1992","journal-title":"Int J Cancer"},{"key":"R22-20230814","first-page":"2149","article-title":"Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug","volume":"48","author":"Pizzorno","year":"1988","journal-title":"Cancer Res"},{"key":"R23-20230814","first-page":"5275","article-title":"Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug","volume":"49","author":"Pizzorno","year":"1989","journal-title":"Cancer Res"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1016\/S0021-9258(18)38101-8","article-title":"Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines","volume":"266","author":"McCloskey","year":"1991","journal-title":"J Biol Chem"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/23808993.2018.1517025","article-title":"Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylation revisited","volume":"3","author":"Muller","year":"2018","journal-title":"Expert Rev Precis Med Drug Dev."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.V93.3.1067","article-title":"Differential methotrexate resistance in childhood T- versus common\/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay","volume":"93","author":"Rots","year":"1999","journal-title":"Blood."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0959-8049(00)00433-0","article-title":"A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia","volume":"37","author":"Rots","year":"2001","journal-title":"Eur J Cancer"},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI118409","article-title":"Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate","volume":"97","author":"Masson","year":"1996","journal-title":"J Clin Invest"},{"key":"R29-20230814","first-page":"667","article-title":"Natural resistance to methotrexate in human acute nonlymphocytic leukemia","volume":"61","author":"Bertino","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"R30-20230814","first-page":"259","article-title":"gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias","volume":"9","author":"Longo","year":"1997","journal-title":"Oncol Res"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199609093433","article-title":"Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia","volume":"21","author":"Matherly","year":"1996","journal-title":"Leuk Lymphoma."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/ard.2004.033399","article-title":"Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study","volume":"64","author":"Dervieux","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2013-203725","article-title":"Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis","volume":"74","author":"de Rotte","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/annrheumdis-2013-203723","article-title":"Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients","volume":"74","author":"Calasan","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"e000363","DOI":"10.1136\/rmdopen-2016-000363","article-title":"Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study","volume":"3","author":"Takahashi","year":"2017","journal-title":"RMD Open"},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.27201","article-title":"Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy","volume":"62","author":"Stamp","year":"2010","journal-title":"Arthritis Rheum."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R39-20230814","first-page":"687","article-title":"Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development","volume":"42","author":"Barredo","year":"1992","journal-title":"Mol Pharmacol."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4757-5241-0_16","article-title":"In vitro methotrexate polyglutamate synthesis by rat liver folylpolyglutamate synthetase and inhibition by bromosulfophthalein","volume":"163","author":"McGuire","year":"1983","journal-title":"Adv Exp Med Biol"},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0003-2697(90)90563-O","article-title":"A microassay for mammalian folylpolyglutamate synthetase","volume":"186","author":"Antonsson","year":"1990","journal-title":"Anal Biochem."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/0003-2697(84)90174-X","article-title":"Measurement of folylpolyglutamate synthetase in mammalian tissues","volume":"140","author":"Moran","year":"1984","journal-title":"Anal Biochem."},{"key":"R43-20230814","first-page":"156","article-title":"Structural features of 4-amino antifolates required for substrate activity with mammalian folylpolyglutamate synthetase","volume":"27","author":"Moran","year":"1985","journal-title":"Mol Pharmacol"},{"key":"R44-20230814","first-page":"317","article-title":"Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity","volume":"7","author":"van der Wilt","year":"1995","journal-title":"Oncol Res"},{"key":"R45-20230814","first-page":"299","article-title":"Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure","volume":"4","author":"Jansen","year":"1992","journal-title":"Oncol Res"},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/rheumatology\/kex223","article-title":"Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial","volume":"56","author":"Konijn","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/annrheumdis-2012-202818","article-title":"A non-inferiority trial of an attenuated combination strategy (\u201cCOBRA-light\u201d) compared to the original COBRA strategy: clinical results after 26 weeks","volume":"73","author":"den Uyl","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem."},{"key":"R49-20230814","first-page":"3874","article-title":"Secretion of gamma-glutamyl hydrolase in vitro","volume":"51","author":"O'Connor","year":"1991","journal-title":"Cancer Res."},{"key":"R50-20230814","first-page":"2426","article-title":"Role of folylpolyglutamate synthetase in the regulation of methotrexate polyglutamate formation in H35 hepatoma cells","volume":"48","author":"Johnson","year":"1988","journal-title":"Cancer Res."},{"key":"R51-20230814","first-page":"3034","article-title":"Folate analogues as substrates of mammalian folylpolyglutamate synthetase","volume":"45","author":"Schoo","year":"1985","journal-title":"Cancer Res"},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ijc.29919","article-title":"Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance","volume":"138","author":"Wojtuszkiewicz","year":"2016","journal-title":"Int J Cancer"},{"key":"R53-20230814","first-page":"1300","article-title":"AB0236\u2005Development and validation of a sensitive lc-ms\/ms-based method for analysis of enzymatic activity of folylpolyglutamate synthetase and methotrexate polyglutamates in peripheral blood mononuclear cells of rheumatoid arthritis patients","volume":"77","author":"Muller","year":"2018","journal-title":"Ann Rheum Dis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:22:20Z","timestamp":1692051740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000638","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}